France’s Strict Medical Cannabis Framework: A Model in the Making?

France may be taking a slower, more cautious path on medical cannabis, but that could be its biggest strength. As highlighted in a recent article by Business of Cannabis, the country’s pharmaceutical-grade approach, reinforced by new documents submitted to the EU in March 2025, sets a high bar for product quality and patient safety.

Augur Associates, in collaboration with Newsweed, explores this in detail in our latest State of the Medical Cannabis Industry in France – 2025 report. France’s model might just become Europe’s blueprint.